

[225] BIOLINERX DEVELOPING NOVEL TREATMENTS WHICH COULD IMPROVE THE ACTIVITY OF CANCER IMMUNOTHERAPY

David Malek¹, ¹ Biolinerx

- **Investment Rational**

BioLineRx is a publicly-traded (NASDAQ/TASE), clinical-stage company focused on oncology and immunology. BioLineRx has a strategic collaboration with Novartis for co-development of selected drugs candidates, under which it has in-licensed three projects last year. BioLineRx has established immunotherapy collaboration with both Merck and Genentech, and recently acquired Agalimmune Ltd., thereby bolstering the company's immuno-oncology pipeline.

- **Business Strategy**

BioLineRx's close ties with research institutions and biotechnology companies, enable access to promising early stage projects. BioLineRx in-licenses and leverages selected early-stage programs through advanced clinical trials and registration. The company partners with medium-large sized pharmaceutical companies to complete clinical development and commercialization.

- **Core Technology**

BL-8040 is a best in class CXCR4 antagonist. It induces migration and infiltration of anti-tumor immune-cells, reduces accumulation of immune-suppressors and induces cancer-cells-apoptosis. Combination of BL-8040 with immune-checkpoints-inhibitors can potentially expand the usage in cancer types currently resistant to immuno-oncology treatments.

AGI-134 is a synthetic α Gal immunotherapy for solid tumors. AGI-134 harnesses the body's pre-existing anti- α Gal-antibodies to induce an anti-tumor response to the patient's own tumor neo-antigens.

- **Product Profile/Pipeline**

BL-8040 is currently undergoing multiple Phase-2 trials for the treatment of SCM, AML and solid tumors in combination with checkpoints-inhibitors.

AGI-134 has completed multiple pre-clinical studies. It demonstrated, not only killing of primary tumor cells, but also second anti-metastatic immune response. Furthermore, it synergism with PD-1 inhibitor can potentially improves the rate and duration of response to immunotherapies.

What's Next?

BioLineRx plans to increase its immuno-oncology activity by in-licensing and strategic transactions of additional novel agents. In addition, BioLineRx will continue to broaden the development of BL-8040 in the fields of immunotherapy and SCM (Phase-2/3 registrational study). AGI-134 is expected to commence a first-in-man study in the first half of 2018. Several additional projects are expected to come under the Novartis collaboration.